Immunotherapy and Targeted Treatment in Solid Tumors: Biomarkers and Novel Therapeutic Strategies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 401
Special Issue Editors
2. Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", 022328 Bucharest, Romania
Interests: clinical diagnosis; cancer; chemotherapy; targeted therapy; immunotherapy; radiotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: precision oncology; molecular profiling; immunotherapy; cancer biomarkers; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue titled “Immunotherapy and Targeted Treatment in Solid Tumors: Biomarkers and Novel Therapeutic Strategies” in Biomedicines. Immunotherapy and targeted therapies have revolutionized the treatment of solid tumors, significantly improving survival rates across multiple cancer types. However, not all patients respond equally to these therapies, and resistance mechanisms remain a major challenge. Understanding the molecular and immunological factors that influence treatment response is essential for advancing precision medicine approaches in oncology.
This Special Issue aims to explore innovative developments in immunotherapy and targeted therapies by focusing on predictive and prognostic biomarkers, combination strategies, and novel therapeutic approaches. The issue aligns with the scope of Biomedicines by emphasizing translational research that bridges molecular discoveries with clinical applications. We seek to provide a comprehensive perspective on optimizing cancer treatments through biomarker-driven strategies and emerging therapeutic innovations.
In this Special Issue, we welcome original research articles and comprehensive reviews. Topics of interest include (but are not limited to) the following research areas:
- Biomarkers for predicting response and resistance to immunotherapy and targeted therapies;
- Tumor microenvironment modulation and immune checkpoint inhibitors;
- Advances in molecular profiling for precision oncology;
- Novel combination strategies to overcome resistance and enhance treatment efficacy;
- The role of the microbiome and host factors in immunotherapy response;
- Translational research in cancer immunotherapy and targeted therapy;
- Development of new agents and treatment paradigms in solid tumors;
- Real-world data and clinical applications of precision oncology.
We look forward to receiving your contributions and collaborating on this exciting research topic.
Dr. Dana Lucia Stănculeanu
Dr. Adelina Silvana Gheorghe
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- targeted therapy
- biomarkers
- tumor microenvironment
- molecular profiling
- precision oncology
- treatment resistance
- solid tumors
- translational oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
